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The Important Roles of Steroid
Sulfatase and Sulfotransferases in
Gynecological Diseases
Tea Lanišnik Rižner *
Faculty of Medicine, Institute of Biochemistry, University of Ljubljana, Ljubljana, Slovenia
Gynecological diseases such as endometriosis, adenomyosis and uterine fibroids,
and gynecological cancers including endometrial cancer and ovarian cancer, affect
a large proportion of women. These diseases are estrogen dependent, and their
progression often depends on local estrogen formation. In peripheral tissues,
estrogens can be formed from the inactive precursors dehydroepiandrosterone
sulfate and estrone sulfate. Sulfatase and sulfotransferases have pivotal roles
in these processes, where sulfatase hydrolyzes estrone sulfate to estrone, and
dehydroepiandrosterone sulfate to dehydroepiandrosterone, and sulfotransferases
catalyze the reverse reactions. Further activation of estrone to the most potent estrogen,
estradiol, is catalyzed by 17-ketosteroid reductases, while estradiol can also be
formed from dehydroepiandrosterone by the sequential actions of 3β-hydroxysteroid
dehydrogenase- 41 -isomerase, aromatase, and 17-ketosteroid reductase. This review
introduces the sulfatase and sulfotransferase enzymes, in terms of their structures and
reaction mechanisms, and the regulation and different transcripts of their genes, together
with the importance of their currently known single nucleotide polymorphisms. Data
on expression of sulfatase and sulfotransferases in gynecological diseases are also
reviewed. There are often unchanged mRNA and protein levels in diseased tissue,
with higher sulfatase activities in cancerous endometrium, ovarian cancer cell lines,
and adenomyosis. This can be indicative of a disturbed balance between the sulfatase
and sulfotransferases enzymes, defining the potential for sulfatase as a drug target
for treatment of gynecological diseases. Finally, clinical trials with sulfatase inhibitors
are discussed, where two inhibitors have already concluded phase II trials, although
so far with no convincing clinical outcomes for patients with endometrial cancer and
endometriosis.
Keywords: endometrial cancer, endometriosis, adenomyosis, uterine fibroids, estrogen formation, estrone sulfate,
dehydroepiandrosterone sulfate
STEROID SULFATASE
The formation and hydrolysis of steroid sulfates by the steroid sulfotransferase (SULT) and
steroid sulfatase (STS) enzymes, respectively, represent important mechanisms in the regulation
of the biological activities of many steroid hormones (Purohit et al., 1998). STS (E.C. 3.1.6.2.)
hydrolyzes estrone sulfate (E1-S) and dehydroepiandrosterone sulfate (DHEA-S) to E1 and
DHEA, respectively (Figure 1), as well as cholesterol sulfate and pregnenolone sulfate to their
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FIGURE 1 | The roles of the STS and SULT enzymes in local estrogen biosynthesis. Synthesis of E2 from DHEA-S by the action of steroid sulfatase (STS),
3β-hydroxysteroid dehydrogenase-14-isomerase (HSD3B1, HSD3B2), aromatase (CYP19A1) and 17-ketosteroid reductase (HSD17B1) or aldo-keto reductase 1C3
(AKR1C3) and CYP19A1; and from E1-S by the action of STS and HSD17B1. Sulfotransferases 2A1 (SULT2A1) and SULT2B1 catalyze the conjugation of DHEA, and
SULT1E1 catalyzes the conjugation of E1. Oxidation of E2 to E1 is catalyzed by HSD17B2.
corresponding unconjugated forms. The sulfatase protein family
includes 17 different human sulfatases, where only STS act on
steroid sulfates (Mueller et al., 2015).
STS has been found in the membranes of the endoplasmic
reticulum and was purified from human placenta (Hernandez-
Guzman et al., 2001). It is a monomer with a molecular mass
of 63 kDa, an N-terminal signal peptide of 21–23 amino acids,
and four potential and two functional (i.e., Asn47, Asn259)
glycosylation sites (Reed et al., 2005). Purified STS has been
crystallized, and its structure has been defined at 2.6-Å resolution
(pdb code 1P49; Hernandez-Guzman et al., 2001, 2003). The
three-dimensional structure of STS shows a globular polar
domain with the catalytic site, and the putative transmembrane
domain that consists of two antiparallel hydrophobic alpha
helices (Hernandez-Guzman et al., 2003) (Figure 2A). STS
includes Ca2+ as a cofactor and 10 catalytically important amino
acid residues: Arg35, Arg36, ARG78, Arg342, Lys134, Lys368,
His136, His290, Gln343 and a formylglycine (FGly75). This
posttranslational modification of Cys75 to FGly75 is mediated
by the FGly-generating enzyme encoded by sulfatase-modifying
factor 1 (Preusser-Kunze et al., 2005).
STS catalyzes the hydrolysis of the sulfate moiety in a four-step
mechanism. According to Ghosh (2007), these steps comprise:
(1) activation of FGly75 by a water molecule; (2) nucleophilic
attack of hydroxy-FGly on the sulfur atom of the substrate (i.e.,
E1-S, DHEA-S), which is facilitated by Ca2+; (3) release of the
free hydroxy-product (i.e., E1, DHEA); and finally (4) release
of HSO−4 and regeneration of FGly (Figure 2B). As a sulfate
moiety covalently linked to hydroxy-FGly has been observed in
the crystal structure of STS, this suggests that the sulfated form of
hydroxy-FGly is the resting state for human STS (Ghosh, 2007).
Kinetics characterization has revealed that purified STS can
hydrolyze DHEA-S and E1-S with µM Km values (Hernandez-
Guzman et al., 2001; Table 1).
The STS gene has been localized to the X chromosome
(Xp22.31), and it spans 146 kb, includes 10 exons, and encodes
a protein of 583 amino acids (Reed et al., 2005). Although eight
tissue-specific STS transcripts have been identified (Nardi et al.,
2009), only six are currently included in the gene database:
isozyme S, and variants X1 to X5 (http://www.ncbi.nlm.nih.
gov/gene). STS transcripts have 235 coding genetic variants
(cSNPs) in the db SNP database (http://www.ncbi.nlm.nih.gov/
SNP; September 2015), although only one of these cSNPs,
Val307Ile, has a minor allele frequency (MAF) >0.01 (0.0172)
(Table 2). SNPs have been reported in the promoter region
and in introns and exons of the STS gene (Brookes et al.,
2010; Matsumoto et al., 2010, 2013). Seven SNPs have been
identified in the Japanese population, including one SNP in the
5′-untranslated region (155G>A), five in the 5′-flanking region,
and one cSNP, Val476Met, with a frequency of 0.014 (Matsumoto
et al., 2010). For three specific SNPs, functional analysis has
revealed significantly decreased (155A) and increased (−2837A,
−1588C) transcriptional activities in a reporter gene assay in
MCF7 cells, but showed no effects at the protein and DHEAS STS
activity levels for Val476Met variant (Matsumoto et al., 2013).
The loss of STS activity due to STS gene deletion or point
mutations results in X-linked ichthyosis, a genetic skin disorder
that affects 1 in 2000 to 1 in 6000 males and is characterized
by typical scaling of the skin epidermis (Gelmetti and Ruggero,
2002). Interestingly, deletions andmutations have been identified
mainly in the regions from 7 to 10 exon, which encodes the C-
terminal substrate binding part (Gelmetti and Ruggero, 2002).
This disease results from the inability to liberate cholesterol from
Frontiers in Pharmacology | www.frontiersin.org 2 February 2016 | Volume 7 | Article 30
Rižner The Estrone Sulfatase Pathway in Gynecological Diseases
FIGURE 2 | Tertiary structure and reaction mechanism of the human
STS enzyme. (A) Structure of the human STS enzyme (pdb 1P49), with
transmembrane helices and the globular domain with the active site with
cofactor Ca2+. (B) The reaction mechanism of the STS enzyme and the roles
of the catalytical amino-acid residues His136, Lys134, His290, and Lys368.
FGly, formylglycine; HFGly, hydroxyformylglycine; HFGlyS,
hydroxyformylglycine sulfate. The scheme was adopted from Ghosh (2007).
cholesterol sulfate, and it affects the incorporation of cholesterol
sulfate in the stratum corneum. It is associated with epidermal
hyperplasia and the formation of additional layers of corneocytes,
which leads to unacceptable sloughing of the skin epidermis
(Maltais and Poirier, 2011; Elias et al., 2014). Kent et al. reported
that boys with this genetic disorder have a significantly increased
risk of attention deficit hyperactivity disorder and autism (Kent
et al., 2008). Interestingly, associations between this disorder and
several SNPs within the STS gene were also reported (Brookes
et al., 2010), where the SNP rs12861247 was significantly
associated with lower STS expression. In contrast to these studies,
Stergiakouli et al. did not confirm these associations, although
they observed associations between the SNP rs17268988 and
symptoms of inattention (Stergiakouli et al., 2011).
FIGURE 3 | Tertiary structure and reaction mechanism of the human
SULT1E1 enzyme. (A) Structure of the human SULT1E1 enzyme in complex
with PAP and E2 (pdb 4JVL). (B) Reaction mechanism and the roles of
catalytical amino-acid residues His107, Lys47, and Ser137. The scheme was
adopted from Thomas and Potter (2013).
STS is ubiquitously expressed, with its highest protein levels
in placenta, and lower levels in breast, skin, liver, lung, ovary,
adrenal gland, endometrium, brain, and some other tissues. The
tissue levels vary across physiological and pathophysiological
conditions, but our current understanding of the regulation of
STS expression is still very limited (Nardi et al., 2009). STS
expression is under the control of estrogens in breast cancer
(Zaichuk et al., 2007), and it is down-regulated by GnRH agonists
(Maitoko and Sasaki, 2004) and danazol (Fechner et al., 2007) in
endometriotic tissue. In endometrium, no significant differences
in STS expression have been reported at the mRNA level between
the proliferative and secretory phases (Colette et al., 2013),
while at the protein level, significant down-regulation was seen
in the late secretory phase, compared to the menstrual phase
(Dassen et al., 2007). STS expression can also be affected by
the inflammatory cytokines: interleukin (IL)1α enhanced STS
expression and mRNA levels in the SKOV3 epithelial ovarian
cancer cell line, but not in the OSE normal ovarian surface
epithelium cell line (Ren et al., 2015), and IL1β suppressed
STS expression in endometrial stromal cells (Matsuoka et al.,
2002). On the other hand, IL6 and tumor necrosis factor (TNF)α
increased STS activity in a breast cancer cell line MCF7 not
changing the mRNA levels, which suggested posttranslational
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TABLE 1 | Kinetics characteristics of the STS and SULT enzymes.
Enzyme Substrate Km vmax vmax/Km Ki References
STS DHEA-S 9.6µM 113.4µmol/h/mg 11.9 Hernandez-Guzman et al., 2001a
E1-S 72.8µM 573µmol/h/mg 7.9 Hernandez-Guzman et al., 2001a
SULT1E1 E1 110 ± 100 nM 4.1 ± 0.1 nmol/h/mg 0.04 Adjei et al., 2003b
E2 29 ±10 nM 6.9 ± 0.1 nmol/h/mg 0.24 Adjei et al., 2003b
SULT2A1 DHEA 2.5 ± 0.7µM 13.6 ± 2.5µmol/h/mg 5.4 6.1µM Lu et al., 2008b
SULT2B1a* DHEA 2.3 ± 0.2µM 0.3 ± 0.01µmol/h/mg 0.13 48µM Geese and Raftogianis, 2001b
SULT2B1b* DHEA 4.4 ± 0.6µM 0.1 ± 0.01µmol/h/mg 0.02 22µM Geese and Raftogianis, 2001b
aPurified STS from human placenta.
bPurified recombinant human enzymes, mean ± SEM values are shown; *SULT2B1a and SULT2B1b are two isoforms.
TABLE 2 | Different transcripts and genetic variants of the STS and SULT genes.
Gene Gene Transcript Size Protein gSNP cSNP
ID information (bp) (aa) Total SYN MAF >0.01
STS 412 Isozyme SNM_000351.4 6377 583 4838 231 93 Val307Ile, 0.0172
Variant X5XM_011545518 6340 578 3772 231 93 Val307Ile, 0.0172
Variant X4XM_011545517 6215 578 3782 231 93 Val307Ile, 0.0172
Variant X3XM_011545516 6662 590 7324 232 93 Val307Ile, 0.0172
Variant X2XM_011545515 7336 590 7365 235 93 Val307Ile, 0.0172
Variant X1XM_005274511 6441 723 7318 232 93 Val307Ile, 0.0172
SULT1E1 6783 Variant X2XM_011532210 723 181 911 88 23 –
Variant X1XM_011532209 1697 294 1337 156 42 –
NM_005420 1805 294 1300 156 42 –
SULT2A1 6822 NM_003167 1987 285 1207 163 48 Ala63Pro, 0.0240
Ala261Thr, 0.0407
SULT2B1 6820 Variant 2NM_177973 1228 365 3190 231 88 Arg33Gln, 0.0178
Variant X1XM_005259182 802 221 935 153 57 –
Variant 1NM_004605 1281 350 1707 220 82 Arg18Gln, 0.0178
gSNP, SNP in gene region; cSNP, SNP within coding region; SYN, synonymous; MAF, minor allele frequency; data from Gene and SNP databases (http://www.ncbi.nlm.nih.gov/gene,
http://www.ncbi.nlm.nih.gov/SNP); as of September 2015.
modifications via STS glycosylation (Newman et al., 2000).
In contrast, Sung et al. recently reported that in prostate
cancer cell line PC-3 both, TNFα and insulin growth factor
II regulate STS expression at the transcriptional level (Sung
et al., 2013). STS expression is also regulated by micro (mi)RNA,
as the overexpression of miR-142-3p significantly reduced STS
mRNA levels in the St-T1b human endometrial stromal cell line
(Kästingschäfer et al., 2015).
STEROID SULFOTRANSFERASES
The SULTs catalyze the transfer of a sulfuryl group from
3′-phosphoadenosine-5′-phosphosulfate (PAPS) to the
target molecule. This conjugation is typically involved
in inactivation/detoxification reactions for a variety of
substrates, such as xenobiotics, therapeutic drugs, toxic
compounds, chemical carcinogens, bile acids, hormones and
neurotransmitters, and it is also an important pathway for
hormonal regulation (Geese and Raftogianis, 2001). The
superfamily of cytosolic human SULTs comprises 13 SULT
genes and spans four families: SULT1 includes three phenol
SULT subfamilies (SULT1A, SULT1B, SULT1C) and an estrogen
SULT (SULT1E1); SULT2s catalyze sulfonation of the hydroxyl
groups of steroids (SULT2A1, SULT2B1); and there are two
orphan SULT families, SULT4 and SULT6 (SULT4A1, SULT6B1)
(reviewed in Geese and Raftogianis, 2001; Lindsay et al., 2008).
SULT2A1 catalyzes the sulfonation of DHEA, androgens and
estrogens, while SULT2B1 catalyzes sulfonation of only DHEA
(Lindsay et al., 2008). Although SULTs in general have broad
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substrate specificity, SULT1E1 (E.C. 2.8.2.4.) has significantly
greater affinity for the estrogens than other SULTs, and it
inactivates E1 and estradiol (E2) with nM Km values (Falany
et al., 1995; Table 1). SULT2A1 (E.C. 2.8.2.14) and SULT2B1
(E.C. 2.8.2.2) both catalyze sulfation of DHEA, although
SULT2A1 shows much higher catalytic efficiency (Lu et al.,
2008). The SULTs need PAPS as a coenzyme, and thus SULT
expression has to be accompanied by expression of at least one of
the two PAPS synthase genes (Mueller et al., 2015).
The SULT1E1 gene has been localized to chromosome 4
(4q13.2), it has eight exons and a length of 20 kb, and it encodes
a protein of 294 amino acids with a molecular mass of 35 kDa
(Falany et al., 1995). Recombinant SULT1E1 has been crystalized,
and the structure of the binary complex with PAPS (pdb code
1HY3; Pedersen et al., 2002) and several ternary complexes,
including a complex with PAP and E2 (pdb code 4JVL; Gosavi
et al., 2013), have been resolved. SULT1E1 is a dimer with an
α/β motif that consists of five parallel β-strands surrounded by
α-helices and a conserved α-helix across this structure (Pedersen
et al., 2002) (Figure 3A). The structure of the SULT1E1–PAP–
E2 complex has revealed that E2 binds to a mostly buried
hydrophobic pocket with the sulfuryl acceptor 3′ hydroxyl within
H-bonding distance of the proposed catalytic His107, and Lys10.
The Phe80 and Phe141 are involved in the positioning of the
steroidal substrate and have been suggested to function as a
steric gate, thus defining substrate specificity (Gosavi et al.,
2013). SULT1E1 has three catalytic amino-acid residues: Lys47,
His107, and Ser137 (Negishi et al., 2001). The proposed reaction
mechanism is as follows: upon binding of PAPS, Ser137 forms
an H-bond with Lys47, thus prevents its interaction with the
bridging oxygen in PAPS and its further hydrolysis; His107
attracts a proton from the substrate hydroxyl (i.e., of E2, DHEA),
and enables nucleophilic attack at the sulfur atom in PAPS. In the
next step, Lys47 interacts with the 5′ phosphate of PAPS, which
help in dissociation of the sulfuryl group and in its transfer to
the substrate. Finally, the reaction products, PAP and E1-S are
released, which completes the catalytic cycle (Gamage et al., 2006;
Tibbs et al., 2015) (Figure 3B). The crystallization and kinetics
data have further suggested that the substrate inhibition that
has been observed at high concentrations is a dead-end complex
where both PAP and E2 are bound (Gosavi et al., 2013).
For the SULT1E1 gene, in addition to the primary transcript,
there are two variant transcripts (i.e., variants X1, X2) that encode
proteins of 294 amino acids and 181 amino acids. Currently
more than 150 cSNPs are included in the SNP database for
SULT1E1, but none show MAF >0.01 (Table 2). Functional
analysis has revealed decreased SULT1E1 activities for two
nonsynonymous coding SNPs: Asp22Tyr and Ala32Val (Adjei
et al., 2003). These cSNPs were found in African-American
(Asp22Tyr) and Caucasian (Ala32Val) populations (Adjei et al.,
2003). Additionally, the SNP rs6259 in the promoter region of
SULT1E1 has been associated with increased risk of endometrial
cancer (Rebbeck et al., 2006; Hirata et al., 2008), and SNPs
∗959 G>A and IVS4-1653 T>C with increased recurrence of
endometrial cancer (Choi et al., 2005).
SULT1E1 is expressed in liver, secretory endometrium, fetal
liver, lung, and kidney (Coughtrie, 2002). Expression of SULT1E1
is regulated by steroid hormones. In the normal endometrium,
the highest expression of SULT1E1 was found for the secretory
phase, which is consistent with regulation by progesterone
(Falany and Falany, 1996; Rubin et al., 1999; Dassen et al.,
2007), although Colette et al. recently reported that SULT1E1
expression is unchanged in the proliferative and secretory phases
(Colette et al., 2013). In endometrial cancer cell line Ishikawa
SULT1E1 is induced by steroid drug tibolone via progesterone
receptor (Falany and Falany, 2006), while in liver it is repressed
by xenobiotic activators of the pregnane X receptor and aryl
hydrocarbon receptor peroxisome proliferator, and activated
via peroxisome proliferator activated receptor α and the liver
X receptor (Duanmu et al., 2007). Furthermore, studies have
implied that SULT1E1 is also epigenetically regulated, as its
expression is induced by the histone deacetylase inhibitor
trichostatin A in MCF10A cells (Fu et al., 2010). SULT1E1
activity is also affected by ubiquitous pollutants, such as the
polychlorinated biphenyls, which act as potent inhibitors with Ki
values in the pM range, and thus they can exert their endocrine
disrupting effects without binding to steroid hormone receptors
(Kester et al., 2000).
The SULT2A1 gene has been localized to chromosome 19
(19q13.3). It has six exons and a total length of 16 kb (Freimuth
et al., 2004), with only one transcript known, which encodes
a protein with 285 amino acids and a molecular mass of
34 kDa (Table 2). Several crystal structures of SULT2A1 binary
complexes have been resolved (Tibbs et al., 2015), including
complexes with DHEA (pdb code 1J99; Rehse et al., 2002) and
PAPS (pdb code 4IFB). The complete kinetic mechanism of
SULT2A1 has been defined, which revealed that the binding
of DHEA and PAPS is random, while the rate-limiting step is
nucleotide release. Here, the potent substrate inhibition with a
Ki of 6.1µM for DHEA can be explained by trapping PAP in a
dead-end complex, which impedes the release of the nucleotide
coenzyme (Wang et al., 2014).
SULT2A1 is expressed in liver, adrenal gland, fetal adrenal,
and fetal liver (Luu-The et al., 1995; Coughtrie, 2002). SULT2A1
has broad substrate specificity, as it can catalyze sulfonation
of many hydroxysteroids, including DHEA, epiandrosterone,
androsterone, testosterone, E2, cholesterol, various bile acids,
pregnenolone, 17-ethinyl-E2 and cortisol (Lindsay et al., 2008).
More than 160 cSNPs have been reported for SULT2A1 (Table 2).
Functional analysis has revealed that the nonsynonymous
SNPs Met57Thr, Glu186Val, Ala63Pro, and Lys227Glu result
in decreased SULT2A1 activity when expressed in COS-1 cells
(Nagata and Yamazoe, 2000). Interestingly, the SULT2A1 SNPs
Ala63Pro, Lys227Glu and Ala261Thr have only been found
in African-American populations, and these might explain the
reported interethnic differences in SULT2A1 activity (Thomae
et al., 2002; Hildebrandt et al., 2007). The SULT2A1 SNP
Ala261Thr has an allele frequency of 13% in African-American
populations (reported MAF, 0.0407) and is located within the
dimerization motif, where it prevents formation of SULT2A1
dimers. Surprisingly Ala261Thr still has 93% of the wild-type
enzyme activity. Also Ala63Pro is quite common, with an
allele frequency of 5% in African-American populations, and a
reported MAF of 0.024 (Table 2).
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The expression of SULT2A1 is regulated at the transcriptional
level by the constitutive androstane receptor and pregnane
X receptor (Echchgadda et al., 2007). As recently shown in
human hepatocytes and the HepG2 cell line, the SULT2A1 gene
is induced by E2 activation of estrogen receptor (ER)α via
classical, direct binding to the estrogen response element, and
via nonclassical, AP-1–mediated mechanisms (Li et al., 2014).
SULT2A1 appears to be regulated also at the epigenetic level, as
shown by induction of SULT2A1 expression after treatment of
MCF7 cells with a histone deacetylase inhibitor (Fu et al., 2010).
In the adrenal gland, the expression of SULT2A1 depends on two
transcription factors: steroidogenic factor 1 and GATA-6 (Saner
et al., 2005).
The SULT2B1 isoforms SULT2B1a and SULT2B1b are
products of alternative transcriptional initiation and mRNA
splicing of the same gene, and are expressed in different tissues.
SULT1B1a is expressed in colon, ovary, and fetal brain, and
SULT2B1b in liver, colon, small intestine, placenta, ovary, uterus,
and prostate (Geese and Raftogianis, 2001). SULT1B1a and
SULT1B1b, which has an additional 23 N-terminal amino-acid
residues, have been cloned and expressed in prokaryotic and
eukaryotic systems, and purified and characterized (Geese and
Raftogianis, 2001; Meloche and Falany, 2001). These enzymes
catalyze sulfonation of 3β-hydroxysteroids, pregnenolone, 17α-
hydroxypregnenolone and DHEA (Geese and Raftogianis, 2001).
The structures of both SULT2B1a and SULT2B1b in binary
complexes with PAP (pdb codes 1Q1Q, 1Q1Z, respectively Lee
et al., 2003) have been resolved, as have two ternary complexes
of SULT1Bb with PAP and pregnenolone (pdb code 1Q2O; Lee
et al., 2003), and with PAP and DHEA (pdb code 1Q22, Lee et al.,
2003; Tibbs et al., 2015).
The SULT2B1 gene has been localized to chromosome 19
(19g13.3), and it comprises six exons with a total length of
48 kb (Geese and Raftogianis, 2001; Meloche and Falany, 2001;
Freimuth et al., 2004). Three transcripts have been identified
(variants 1, 2, X1) that encode proteins of 350, 365, and 221
amino acids (Table 2). Although more than 200 coding SNPs for
SULT2B1 are currently included in the SNP database, there is only
one nonsynonymous SNP: Arg33Gln, withMAF>0.01 (Table 2).
So far, only a few of these SNPs have been studied in more
detail. Recently, Lévesque et al. (2014) reported that SULT2B1
SNPs rs12460535, rs2665582, and rs10426628 are significantly
associated with prostate cancer progression and hormone levels.
The SULT enzymes are known to show profound substrate
inhibition, and SULT2B1 is not an exception. DHEA inhibits
SULT2B1a and SULT2B1b with Ki values of 48µM and 22µM,
respectively (Geese and Raftogianis, 2001). Not much is known
about the regulation of SULT2B1. In normal endometrium,
higher SULT2B1b mRNA levels have been seen in the mid-luteal
phase, in agreement with progesterone regulation (Koizumi
et al., 2010). In human endometrial stromal cells, the levels of
SULT2B1b transcript were increased by cAMP or progesterone,
while they were increased by cAMP or relaxin in endometrial
epithelial cells, stimulating protein kinase A pathway (Koizumi
et al., 2010). In prostate cancer cells, expression of SULT1B1b was
shown to be regulated by vitamin D via heterodimer of vitamin
D receptor and retinoid X receptor α (Seo et al., 2013).
LOCAL PRODUCTION OF ESTROGENS
FROM DHEA-S AND E1-S
STS and SULTs have pivotal roles in estrogen synthesis in
peripheral tissues, and thus also in pre-receptor regulation of
steroid hormone action. In premenopausal women, estrogens
can be synthesized in the ovaries and in peripheral tissues
(Labrie, 1991; Simpson, 2003). After menopause, when the
ovaries cease to act, estrogens are formed only in the peripheral
sites, which mainly include adipose tissue, but also bone,
vascular endothelium, aortic smooth muscle cells, and brain
(Simpson, 2003). Locally, estrogens can be formed from
the inactive precursors of adrenal origin, DHEA-S, DHEA,
and androstenedione, and of ovarian origin, DHEA and
androstenedione, or from circulating E1-S (Figure 1). These
steroid precursors are at relatively high concentrations in the
blood of premenopausal and postmenopausal women, with
DHEA-S at 3.4 ± 1.7µM and 1.6 ± 1.0µM, respectively (Labrie
et al., 2006). DHEA and androstenedione are at 15.5 ± 7.6 nM
and 3.4 ± 1.2 nM respectively, in premenopausal women, and
6.8 ± 4.1 nM and 1.4 ± 0.6 nM, respectively, in postmenopausal
women (Labrie et al., 2006). Estrogens can thus be produced
via the so-called aromatase pathway, from androstenedione and
testosterone, by the actions of aromatase and 17-ketosteroid
reductases (i.e., 17β-hydroxysteroid dehydrogenases; HSD17B),
mainly HSD17B1. Estrogens can also be formed from DHEA-
S by the actions of STS, 3β-hydroxysteroid dehydrogenases-
1
4-isomerase (HSD3B1, HSD3B2), aromatase (CYP19A1) and
HSD17B or aldo-keto reductase 1C3 (AKR1C3) and CYP19A1,
and from E1-S by the actions of STS and HSD17B (Rižner, 2013;
Figure 1). The formation of E2 from E1-S is known as the STS
pathway. E1-S is the most important estrogen in the peripheral
blood, at 1.8 ± 1.1 nM and 0.6 ± 0.03 nM in premenopausal
and postmenopausal women, respectively (Caron et al., 2009;
Labrie et al., 2009). Studies in breast and endometrial cancers
have shown that the STS pathway prevails over the aromatase
pathway (Pasqualini et al., 1996; Chetrite et al., 2000; Purohit
et al., 2011; Rižner, 2013). Higher E1-S, E1, and E2 plasma
concentrations were observed for patients with breast cancer and
endometrial cancer, compared to control women (Lépine et al.,
2010; Tworoger et al., 2014) and high E1-S and E2 have been
measured in breast cancer tissue (Chetrite et al., 2000), with high
E2 and a high E2 to E1-S ratio reported in endometrial cancer
tissue (Naitoh et al., 1989; Berstein et al., 2003).Most importantly,
the levels of estrogens in breast and endometrial cancer tissue
are 2- to 40-fold higher compared to plasma concentrations
(Pasqualini et al., 1996; Berstein et al., 2003), further supporting
intracrine formation and actions of estrogens.
DHEA-S and E1-S can thus serve as precursors for E2
formation after their translocation into cells via the transporter
proteins of the organic anion-transporting polypeptide and
organic anion-transporter families (Mueller et al., 2015). STS can
then hydrolyze DHEA-S and E1-S to DHEA and E1, respectively,
while the SULTs can catalyze the reverse reactions. SULT1E1
inactivates E1 and E2 to form the corresponding sulfates, and
SULT2A1 and SULT2B1 conjugate DHEA (Raftogianis et al.,
2000; Meloche and Falany, 2001; Gamage et al., 2006; Pasqualini,
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2009). The sulfated steroids can then be excreeted from the cells
via the ABC transporters (Mueller et al., 2015). The resulting
increased uptake together with the decreased excretion of DHEA-
S and E1-S, and the disturbed delicate balance between the
STS and SULT enzymes, might thus lead to increased levels
of estrogens, which are associated with hormone-dependent
diseases, including several gynecological diseases.
SULFATASE AND SULFOTRANSFERASES
IN GYNECOLOGICAL DISEASES
Benign gynecological diseases such as endometriosis,
adenomyosis, and uterine fibroids, and gynecological cancers
such as endometrial cancer and ovarian cancer, affect a large
proportion of women. The benign diseases are associated with
infertility, and they can significantly decrease quality of life, while
gynecological cancers comprise more than 10% of cancer-related
deaths in women worldwide (Ferlay et al., 2013). These diseases
are mainly hormone-dependent and thus rely on the local
formation of active steroid hormones.
Sulfatase and Sulfotransferase in
Endometriosis
Endometriosis is a frequent benign gynecological disease that
is characterized by the presence of endometrial tissue outside
the uterine cavity. In the general population of women of
reproductive age, the predicted prevalence of endometriosis is
6–10%, but the frequency increases to 30–50% in women with
pain, infertility, or both (Guo and Wang, 2006; Rogers et al.,
2013). Ectopic endometrial tissue can be found in different
parts of the peritoneal cavity, where these locations define
three different entities with different etiologies and pathogenesis:
ovarian, peritoneal, and deep infiltrating endometriosis (Brosens
and Benagiano, 2011). Endometriosis is an estrogen-dependent
disease where endometriotic tissue proliferates in response
to systemic estrogens and estrogens formed locally through
the aromatase and the sulphatase pathways (Huhtinen et al.,
2009; Rižner, 2009). However, the STS pathway appears to
outperform the aromatase pathway, as the aromatase activity in
endometriotic tissue is negligible when compared to STS activity
(Purohit et al., 2008; Delvoux et al., 2009).
Data on expression of STS in endometriosis have remained
relatively contradictory (Table 3). Although metabolism studies
have revealed significantly lower STS activity in ectopic than
eutopic endometrium of patients with ovarian endometriosis
(Carlström et al., 1988), significantly higher levels of STS mRNA
were seen for samples of ovarian endometriosis compared
to eutopic endometrium from control patients (Smuc et al.,
2007, 2009). Also, in peritoneal endometriosis, STS activity
was lower in ectopic than matched eutopic endometrium,
but it still correlated with severity of disease and was higher
in moderate/severe disease vs. minimal/mild disease (Purohit
et al., 2008). At the mRNA level, Collete et al. observed
no significant differences between peritoneal endometriosis
(ectopic) and control (eutopic) endometrial tissue but found
higher levels in deep infiltrating endometriosis compared to
ovarian endometriosis (Colette et al., 2013). Deep infiltrating
endometriosis, Dassen et al. found no differences in STS
expression between ectopic and eutopic endometrium of patients
and the normal endometrium of the control group, while they
found significantly lower protein levels of STS in epithelial cells
TABLE 3 | Expression of STS and SULTs in endometriosis.
Gene Level Regulation References
STS mRNA OE/control endometrium Smuc et al., 2007, 2009
≈ DIE/eutopic/normal endometrium Dassen et al., 2007
DIE/OE; ≈ PE/OE/eutopic endometrium Colette et al., 2013
Protein eutopic/normal endometrium Dassen et al., 2007
≈ ectopic/eutopic endometrium Colette et al., 2013
Activity (E1-S) ectopic/eutopic Carlström et al., 1988
PE/eutopic endometrium Purohit et al., 2008
moderate/severe/minimal/mild Purohit et al., 2008
≈ ectopic/eutopic/control endometrium Delvoux et al., 2009
SULT1E1 mRNA ≈ OE/control endometrium Smuc et al., 2007, 2009
DIE/normal endometrium Dassen et al., 2007
≈ DIE, OE, PE/eutopic endometrium Colette et al., 2013
OE/normal endometrium Hevir et al., 2013
OE/eutopic endometrium Borghese et al., 2008
Protein ≈ OE, PE/eutopic/control endometrium Hudelist et al., 2007
SULT2B1 mRNA OE/normal endometrium Hevir et al., 2013
OE, ovarian endometriosis; PE, peritoneal endometriosis; DIE, deep infiltrating endometriosis.
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of eutopic endometrium compared to normal endometrium
(Dassen et al., 2007). Delvoux et al. reported unchanged STS
activity in samples from all three types of endometriosis (Delvoux
et al., 2009). However, Purohit et al. reported that STS activity in
peritoneal ectopic implants and matched eutopic endometrium
was higher than aromatase activity, which thus suggested that
the STS pathway is important in estrogen formation and that
STS inhibitors might be useful for treatment of endometriosis
(Purohit et al., 2008; Delvoux et al., 2009).
In addition to STS, SULTs should also be taken into account
when evaluating the importance of the STS pathway, as both
of these enzymes affect the subtle balance between estrogen
activation (E1-S hydrolysis) and estrogen inactivation (E1, E2
sulfation). Expression of SULTs has been investigated in several
studies (Table 3). In ectopic tissue of patients with ovarian,
peritoneal, and deep infiltrating endometriosis, no significant
differences in the expression of SULT1E1 was seen at the mRNA
level (Smuc et al., 2007, 2009; Colette et al., 2013), while there
were significantly higher mRNA levels in ectopic endometrium
of deep infiltrating endometriosis, when compared to the normal
endometrium (Dassen et al., 2007). On the other hand, Borghese
et al. and Hevir et al. found decreased mRNA levels in ovarian
endometriosis vs. control eutopic endometrium from patients
(Borghese et al., 2008) and control normal endometrium (Hevir
et al., 2013), respectively. At the protein level, Hudelist et al.
saw no differences between ovarian and peritoneal endometriotic
lesions and eutopic endometrium (Hudelist et al., 2007). The
expression of SULT2A1 has not been studied in this context, but
the expression of SULT2B1 at the mRNA level was decreased in
ovarian endometriosis compared to normal endometrium (Hevir
et al., 2013); which implies that DHEA-Smay serve as a precursor
steroid in this ectopic tissue.
Data on the expression of the STS and SULT genes at the
mRNA, protein and enzymatic activity levels in endometriosis
tissue vs. control tissue are contradictory and do not fully
support the importance of the sulfatase pathway. As different
types of endometriosis show variations in the expression of these
genes, it seems that the sulfatase may have roles primarily in
ovarian endometriosis. Furthermore, the majority of studies have
compared endometriotic tissue with eutopic endometrium of
the same patient, which might not be the optimal study design.
Nowadays, it is generally accepted that eutopic endometrium
of endometriosis patients has already undergone pathological
transformations, and that the gene expression profile in this tissue
can be used as a biomarker of endometriosis (Burney et al., 2007).
Sulfatase and Sulfotransferase in
Adenomyosis
Adenomyosis is a benign gynecological disease that is defined
as the presence of endometrial glands and stroma within the
muscular layer of the uterus (i.e., myometrial tissue) (Kitawaki,
2006; Graziano et al., 2015). The symptoms that appear in
two-thirds of patients with adenomyosis are dysmenorrhea,
metrorrhagia, chronic pelvic pain, dyspareunia, and infertility.
The prevalence of adenomyosis varies among studies, with 5–
70% reported (Graziano et al., 2015). Adenomyosis mainly affects
TABLE 4 | Expression of STS in adenomyosis.
Gene Level Regulation References
STS Protein adenomyotic tissue/basilar
layer of endometrium
Ezaki et al., 2001
Activity
(E1-S)
STS danazol treatment Yamamoto et al., 1993
women in late reproductive age and regresses after menopause
(Kitawaki, 2006). It is thus considered an estrogen-dependent
disease, and is often associated with other estrogen-dependent
pathologies, such as endometriosis, leiomyoma, and hyperplasia,
and also with endometrial cancer (Kitawaki, 2006). Furthermore,
expression of aromatase in adenomyotic tissue is also implicative
of estrogen dependency (Kitawaki et al., 1997). However, the STS
pathway for the local formation of estrogens has been studied by
only two groups (Table 4). Ezaki et al. observed increased STS
protein levels in adenomyotic tissue vs. the basilar layer of normal
endometrium (Ezaki et al., 2001), and Yamamoto et al. reported
increased E1-S STS activity in adenomyosis, which was reduced
by danazol treatment (Yamamoto et al., 1993). Although the
involvement of estrogens in the pathophysiology of adenomyosis
has not been sufficiently studied, and thus further investigations
into estrogen biosynthesis and actions in this gynecological
disease are warranted, the published data indicates importance
of the sulfatase pathway.
Sulfatase and Sulfotransferase in Uterine
Fibroids
Uterine fibroids (leiomyomas; myoma uteri or uterus
myomatosus) are benign tumors of the myometrium that
occur in up to 70% of women of reproductive age (Bulun, 2013).
However, the clinically significant symptoms that include heavy
menstrual bleeding, anemia, difficulties with conceiving, and
increased risk of miscarriage, are seen in one-third of the affected
population (Bulun, 2013). Uterine fibroids appear after menarche
and decline after menopause, which implicates the estrogens
as the primary factor that drives their growth. Additionally,
studies showed that estrogens are necessary, but not sufficient
for proliferation and progesterone also has an important role in
growth of leiomyomas. Estrogens act via estrogen receptor α and
thus stimulate expression of progesterone receptors and further
pro-proliferative action of progesterone (Moravek et al., 2015).
Based on PubMed searches, there has been only one report
on the STS pathway in myoma tissue (Table 5). The Okada
group examined E1-S hydrolysis and E1 sulfation in myoma
tissue vs. myometrium, and they showed decreased STS and
increased SULT activities (Yamamoto et al., 1990, 1993), thus
suggesting that more estrogens can be formed in the surrounding
myometrium than in the myoma tissue. In this way, estrogens
might still act in a paracrine manner to provide myoma tissue
with the mitogenic E2. As other studies showed that aromatase
is upregulated, the local estrogen formation via the aromatase
pathway probably has more important role. Furthermore, the
effects of gonadotropin-releasing hormone analogs on the levels
of estrogens and STS activity have also been examined in myoma
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TABLE 5 | Expression of STS and SULT in myoma uteri.
Gene Level Regulation References
STS Activity (E1-S) myoma vs. myometrium Yamamoto et al., 1990
SULT1E1 Activity (E1) myoma vs. myometrium Yamamoto et al., 1990
where lower levels of estrogens (Pasqualini et al., 1990; van de
Ven et al., 2002) and no significant effects on STS activity (van
de Ven et al., 2002) were seen. So far the roles of the sulfatase
pathway in uterine fibroids have not been thoroughly examined,
which calls for further studies.
Sulfatase and Sulfotransferase in
Endometrial Cancer
Endometrial cancer is the most common gynecological
malignancy in the developed world. Worldwide, 319,605 new
cases of endometrial cancer and 76,160 deaths were estimated for
2012 (Ferlay et al., 2013). Based on histopathology, the majority
of endometrial cancers can be divided into two groups: type 1
with an endometrioid histology, which comprises 70–80% of all
cases (Yeramian et al., 2013); and type 2 with serous papillary
or clear-cell histology, which comprise 20% of all cases. Type
1 endometrial cancer is considered to be estrogen dependent,
and type 2 not to be associated with hyper-estrogenic factors
(Amant et al., 2005; Ryan et al., 2005). Development of type
1 endometrial cancer is usually explained by the unopposed
estrogen hypothesis, which proposes that exposure to estrogens
(of either endogenous or exogenous origins) that is not opposed
by progesterone or synthetic progestins increases the mitotic
activity of endometrial cells and the number of DNA replication
errors. This can lead to somatic mutations that can result
in malignant phenotypes (Henderson and Feigelson, 2000;
Akhmedkhanov et al., 2001; Inoue, 2001; Sonoda and Barakat,
2006). In line with intracrine estrogen action the formation
of estrogens has been detected in proliferative and secretory
endometrium and in endometrial cancer tissues (Tseng et al.,
1982). Additionally, increased E2 concentrations have been
reported in cancerous endometrium of premenopausal and
postmenopausal women with type 1 and type 2 endometrial
cancer (Bonney et al., 1986; Berstein et al., 2003), and higher E1-S
plasma concentrations were observed for endometrial cancer
patients, compared to control healthy postmenopausal women
(Jasonni et al., 1984).
Expression of STS and its activity in endometrial cancer
have been evaluated in nine studies (Table 6). No significant
differences in STS expression (Smuc and Rizner, 2009) and
increased mRNA levels of STS (Lépine et al., 2010) have
been reported in endometrial cancer vs. adjacent control
tissue. At the cellular level, STS immunoreactivity in
endometrial cancer tissue was higher compared to normal
endometrium (Utsunomiya et al., 2004), which suggests
increased availability of the biologically active estrogens. In line
with this, immunohistochemical data and early metabolism
studies have shown significantly higher E1-S STS activity in
endometrial cancer tissue, compared to control endometrium
(Adessi et al., 1984; Prost et al., 1984; Naitoh et al., 1989; Urabe
et al., 1989). However, more recently, Tanaka et al. reported
lower E1-S STS activity in cancerous tissue, compared to normal
endometrium (Tanaka et al., 2003). This discordance might be
explained by the different control groups or menopausal stages
of the cases and controls. Increased DHEA-S STS activity has
also been observed in endometrial cancer, compared to normal
endometrium (Abulafia et al., 2009).
In cancerous and adjacent control endometrium, SULT1E1
mRNA levels were reported to be unchanged or borderline
significantly up-regulated (Lépine et al., 2010; Hevir et al.,
2011; Table 6). The study by Lépine et al. (2010) included
26% type 2 endometrial cancer patients, which might explain
these differences observed. At the cellular level, SULT1E1
immunoreactivity was diminished (Utsunomiya et al., 2004)
or was not detected (www.proteinatlas.org; Uhlén et al., 2015)
in endometrial cancer, compared to normal endometrium,
while in other studies, increased SULT1E1 staining has been
observed in cancerous endometrium, compared to adjacent
control endometrium (Xu et al., 2012). These differences can
be explained by different antibodies used. As SULT2A1 is not
expressed in either endometrial cancer or adjacent control
endometrium (Rubin et al., 1999), SULT2B1 is the major DHEA-
specific SULT enzyme in endometrial cancer, and increased
SULT2B1 expression has recently been reported in endometrial
cancer, compared to adjacent control endometrium (Hevir
et al., 2011). Also Human Protein Atlas data show medium
to high staining of cancerous endometrium with two different
anti-SULT2B1 antibodies (Uhlén et al., 2015), which further
supports the conclusion that despite of increased DHEA-S STS
activity, DHEA-S may not represent the steroid precursor for E2
formation in cancerous endometrium.
Although the expression of the STS and SULT1E1 genes in
diseased vs. control endometrium has differed between studies
(Table 6), all of the published data show higher mRNA and
protein levels for STS than SULT1E1 in endometrial cancer tissue
vs. control endometrium. The majority of the published data also
shows increased E1-S STS activity in endometrial cancer, and
thus supports E2 formation via the STS pathway.
Sulfatase and Sulfotransferase in Ovarian
Cancer
Ovarian cancer is the sixth leading cause of cancer-related death
in the developed world. Worldwide, there were 238,719 new
cases and 151,905 deaths estimated for 2012 (Ferlay et al., 2013).
Most patients are diagnosed when they show advanced stage
disease with poor prognosis. Ovarian cancer is a heterogeneous
disease that encompasses several types of tumors, with large
differences in histopathological features and clinical behaviors.
Epithelial ovarian cancers are the most frequent tumors, which
account for around 98% of all cases. These can be defined
into distinct diseases, as serous (75%), endometrioid (10%),
clear-cell (5–10%), and mucinous (5–10%) ovarian cancers,
which are usually grouped into low-grade or high-grade tumors
(Guarneri et al., 2011). Nowadays, it is widely accepted that
serous, mucinous, endometrioid, clear cell, and other histotypes
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TABLE 6 | Expression of STS and SULTs in endometrial cancer.
Gene Level Regulation References
STS mRNA ≈ Cancer/adjacent tissue; EC type 1 Smuc and Rizner, 2009
Cancer/adjacent tissue; EC type 1 (74%) and type 2 (26%) Lépine et al., 2010
Protein 86% EC Utsunomiya et al., 2004
82% Cancer weak to moderate/normal endometrium weak (glandular cells) Human Protein Atlas
Activity (E1-S) EC/normal endometrium Adessi et al., 1984; Prost et al., 1984; Naitoh et al., 1989;
Urabe et al., 1989
EC/normal endometrium Tanaka et al., 2003
DHEA-S EC/normal endometrium Abulafia et al., 2009
SULT1E1 mRNA ≈ Cancer/adjacent tissue; EC type 1 Hevir et al., 2011
Borderline Cancer/adjacent tissue; EC type 1 (74%) and type 2 (26%) Lépine et al., 2010
Protein 22% EC Utsunomiya et al., 2004
EC/adjacent endometrium Xu et al., 2012
Not detected in cancer Human Protein Atlas
SULT2B1 mRNA Cancer/adjacent tissue; EC type 1 Hevir et al., 2011
Protein Moderate staining in cancer Human Protein Atlas
EC, endometrial cancer.
of ovarian cancers representmolecularly and etiologically distinct
diseases (Vaughan et al., 2011). The etiology of ovarian cancer
can be explained by the “incessant ovulation theory” and
the “gonadotropin theory” (Stadel, 1975; Fathalla, 2013). An
increasing body of data suggests that ovarian cancer is estrogen
dependent, although the role of estrogens in this disease has not
yet been investigated thoroughly (Chura et al., 2009). Genetic
susceptibility studies have associated SNPs in the ESR2 gene
that codes for ERβ with significantly increased risk of ovarian
cancer (Lurie et al., 2011), and epidemiological studies (Women’s
Health Initiative and Million Women Studies: (Anderson et al.,
2003; Beral et al., 2007) have also suggested that both estrogen
only and estrogen–progestin hormone replacement therapies
increase the risk of ovarian cancer (Modugno et al., 2012).
However, the current lack of knowledge warrants further studies
on the mechanisms of steroid hormone actions in ovarian cancer,
followed by clinical trials that may also target estrogen actions.
The expression of STS has been studied at the mRNA and
protein levels (Table 7). No significant differences were reported
between epithelial ovarian carcinoma and ovarian surface
epithelia tissue and primary cell cultures at the mRNA and
protein levels (Ren et al., 2015). However, Okuda et al. detected
STS staining in 70% of ovarian clear-cell adenocarcinoma, 33% of
serous adenocarcinoma and 50% of mucinous adenocarcinoma,
thus suggesting the importance of STS in this pathophysiology
(Okuda et al., 2001). In contrast to these data, the Human
Protein Atlas reports low to medium expression of STS in only
two samples of mucinous adenocarcinoma out of 12 serous,
mucinous and endometrioid ovarian cancer samples (Uhlén
et al., 2015). The STS activity has been studied by two groups:
Ren et al. reported higher activity in the SKOV-3 and PEO
epithelial ovarian carcinoma cell lines vs. the OSE normal ovarian
surface epithelium cell line (Ren et al., 2015), and Chura et al.
reported correlations between increased STS activity and lower
progression-free survival of patients (Chura et al., 2009).
The expression of the SULT1E1 gene has only been
investigated by one group (Ren et al., 2015; Table 7). They
reported that SULT1E1 expression was down-regulated in
epithelial ovarian carcinoma vs. the OSE normal ovarian surface
epithelium cell line, and also that SULT activity was lower in
SKOV-3 and PEO cells vs. OSE cells. This all supports the
importance of local estrogen formation via the STS pathway
(Ren et al., 2015). Using three different anti-SULT1E1 antibodies,
SULT1E1 was detected in two of 12 cores of ovarian cancer,
with low to high staining observed mainly in mucinous ovarian
cancer (Uhlén et al., 2015). With two polyclonal anti-SULT2A1
antibodies, SULT2A1 was detected in two to six of 12 cores,
with low to medium intensity, while with three different anti-
SULT2B1 antibodies, medium to high intensity staining was
reported for SULT2B1 in seven to 12 of 12 tissue microarray
cores (Uhlén et al., 2015). To date, there have been no other
reports on the expression of SULT2A1 and SULT2B1 in ovarian
cancer. Based on these data, DHEA-S cannot be excluded as
a potential precursor molecule for local estrogen formation in
ovarian cancer.
SULFATASE AS A TARGET FOR
TREATMENT OF GYNECOLOGICAL
DISEASE
There is a plethora of data that supports the important role
of STS in individual gynecological diseases, with disturbances
reported for the balance between the STS and SULT enzymes.
Although the observed STS mRNA and protein levels were rarely
increased, higher STS activities have been seen in the majority of
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TABLE 7 | Expression of STS and SULTs in ovarian cancer.
Gene Level Regulation References
STS mRNA ≈ EOC/OSE Ren et al., 2015
Protein Expressed EOC and OSE Ren et al., 2015
70% OCCA; 33% serous and 50% mucinous adenocarcinoma Okuda et al., 2001
17% Cancer low/moderateNormal ovary low (stromal cells) Human Protein Atlas
Activity (E1-S) SKOV-3, PEO-1 vs. OSE Ren et al., 2015
STS progression-free survival Chura et al., 2009
SULT1E1 mRNA EOC/OSE Ren et al., 2015
Protein Expressed EOC and OSE Ren et al., 2015
17% Cancer moderate/normal ND Human Protein Atlas
Activity (E1) SKOV-3, PEO-1 vs. OSE Ren et al., 2015
SULT2A1 Protein 17%-50% Cancer low/moderateNormal ovary/ND Human Protein Atlas
SULT2B1 Protein 58%-100% Cancer moderateNormal ovary/weak Human Protein Atlas
EOC, epithelial ovarian carcinoma; OSE, ovarian surface epithelia; OCCA, ovarian clear-cell adenocarcinoma.
pathological tissues and in model cell lines, including cancerous
endometrium (Adessi et al., 1984; Prost et al., 1984; Naitoh et al.,
1989; Urabe et al., 1989; Day et al., 2009), ovarian cancer cell lines
(Day et al., 2009; Ren et al., 2015), and adenomyosis (Yamamoto
et al., 1993; Ezaki et al., 2001). This is in line with the higher
catalytic efficiency of STS vs. SULT (Table 1), and in some cases,
higher expression levels of STS (Tables 3, 6). Furthermore, in
endometriosis, endometrial cancer, and ovarian cancer, the STS
pathway has been shown to prevail over the aromatase pathway
(Purohit et al., 2008; Fournier and Poirier, 2009; Hevir-Kene and
Rižner, 2015; Ren et al., 2015), which substantiate the potential of
STS as a drug target.
Lack of correlation between STSmRNA levels and STS activity
imply that post-translational modifications might increase STS
activity. Additionally, increased uptake and decreased excretion
of the sulfated steroids might also be recognized as enhanced STS
activity, which would explain why RNA levels are less informative
(Newman et al., 2000). As not much is known about the transport
of E1-S and DHEA-S across the plasma membrane in these
diseased tissues, their uptake and excretion should be studied, as
this will help us to better understand local estrogen formation
and actions.
SULFATASE INHIBITORS AND CLINICAL
TRIALS
The development of STS inhibitors started in the 1990s, and to
date, this has led to two compounds that have entered clinical
trials (Poirier, 2015). STS inhibitors have been developed by
several research groups and several pharmaceutical companies,
and the current status of this field has been a topic of
several educative reviews in the last few years (Mostafa and
Taylor, 2013; Sadozai, 2013; Thomas and Potter, 2013, 2015;
Williams, 2013; Poirier, 2015). In general, the large number
of STS inhibitors known to date can be divided into steroidal
and nonsteroidal compounds, and further into sulfomoylated
and nonsulfomoylated compounds (Maltais and Poirier, 2011).
Among the steroidal compounds, estrogen O-sulfamates have
been the most intensively studied in in-vitro and in-vivo models.
These have included E1-3-O-sulfamate (EMATE) and E2-3-O-
sulfamate (E2MATE), where EMATE was identified as the first
irreversible STS inhibitor, although it was originally developed
as a prodrug for estrogen replacement therapy (Sadozai, 2013;
Thomas and Potter, 2015).
Nonsteroidal inhibitors have also been developed, and an
irreversible STS inhibitor, 667 Coumate (also known as STX64
and BN83495, and more recently referred to as irosustat), shows
higher potency than EMATE (IC50, 8 nM vs. 25 nM, at 20µM
E1-S, against STS from placental microsomes) (Woo et al., 2000).
This compound has high bioavailability, which was explained by
its sequestration within erythrocytes, where it binds to carbonic
anhydrase II (IC50, 25 nM) (Ho et al., 2003). A plethora of
EMATE and 667 Coumate derivatives have been developed in
the last few years as 2nd and 3rd generation STS inhibitors
(Sadozai, 2013; Thomas and Potter, 2015). These have included
the steroidal compound KW-2581 that showed no estrogenic
activity (Ishida et al., 2007), and STX213 and STX1938, which
have shown greater potency than 667 Coumate (Foster et al.,
2008b).
In addition to classical STS inhibitors, dual inhibitors that
target STS and aromatase have also been developed (Sadozai,
2013), as well as compounds with dual actions as STS inhibitors
and prodrugs of selective estrogen modulators (Sadozai, 2013).
Here, the nonsteroidal dual aromatase–STS inhibitor STX681
has shown great potential for treatment of hormone-dependent
breast cancer (Foster et al., 2008a), and the dual sulfamate
STS inhibitor and antiestrogen SR16157 has also been studied
(Rasmussen et al., 2007; Sadozai, 2013).
The published data imply that inhibitors of STS have the
potential for treatment of individual gynecological diseases.
In the case of endometriosis, STS activity correlates with the
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severity of this disease, and Purohit et al. reported that the
STS inhibitor STX64 almost completely blocked STS activity
in vitro in eutopic and ectopic tissue from patients with
peritoneal endometriosis (Purohit et al., 2008). Furthermore,
E2MATE inhibited STS activity in endometrial tissue in vitro
and in vivo in animal models, including in mouse uterus,
liver, leukocytes and endometriotic lesions (Colette et al., 2011).
Also, the inhibitor STX64 has been investigated in intact
mouse endometrial cancer xenografts and ovariectomized mouse
endometrial cancer xenograft models, and in the latter case,
STX64 showed significant inhibition after daily 1–10mg/kg oral
doses (Foster et al., 2008c), thus demonstrating the great potential
of STS inhibitors as novel anticancer drugs. To the best of our
knowledge, STS inhibitors have not yet been investigated in
ovarian cancer, adenomyosis and myoma uteri, neither in vitro
nor in vivo.
Several clinical studies have already been performed with
STS inhibitors (Thomas and Potter, 2015). Irosustat (i.e.,
667 Coumate) was the first STS inhibitor to enter phase I
clinical trials, in post-menopausal women with ER-positive
breast cancer (NCT01840488); (Stanway et al., 2006). Later, two
phase II clinical studies were reported in breast cancer patients
(ClinicalTrials.gov): the IPET trial was designed to look at the
effects of irosustat using positron emission tomography scanning
(Thomas and Potter, 2015), while the IRIS trial investigated the
effects of combined treatment with irosustat and anastrozole (an
aromatase inhibitor) (NCT01785992). Unfortunately no study
data are publicly available for these trials.
Irosustat has also been investigated in ER-positive
advanced/recurrent endometrial cancer in a phase II study
(NCT00910091). In this study, irosustat was evaluated vs.
progestin megestrol acetate in 73 patients, with median age 68
years (range, 37–85 years). Here, 36 patients were randomized
to irosustat (40 mg/day), and 37 to megestrol acetate (160
mg/day) (Pautier et al., 2012). After 6 months of treatment, 36.1
and 56.8% of the patients treated with irosustat and megestrol
acetate, respectively, were alive and without disease progression.
Progression free survival was 16 and 32 weeks for irosustat
and megestrol acetate, respectively. Thus, in patients with
advanced and recurrent disease, irosustat showed much lower
clinical benefit compared to progestin megestrol acetate, which
questioned the suitability of STS inhibitors for treatment of
endometrial cancer.
In a murine model, E2MATE reduced the weight of the
endometriotic lesions, but had no effects on proliferation and
apoptosis, or on STS expression (Colette et al., 2011), which
led the Swiss-based biopharmaceutical company PregLem to
investigate E2MATE in endometriosis patients. As described by
Pohl et al. they first examined the effects of E2MATE in a
phase I study (SAPHIR; EudraCT number: 2007-005662-12) in
healthy women of reproductive age, through which they showed
that E2MATE can inhibit STS in peripheral blood mononuclear
cells, although it failed to inhibit STS in eutopic endometrium
(Pohl et al., 2014). As a continuation, they investigated
the effects of E2MATE (4 mg/week) and/or norethindrone
acetate (NETA; 10 mg/day) in healthy nonpregnant women
of reproductive age (i.e., 24–39 years). Twenty-four women
were randomized to E2MATE, NETA or the combination
E2MATE+NETA, for 4 weeks of treatment and 12 weeks of
follow-up. In both the E2MATE and E2MATE+NETA groups,
the STS activity in peripheral blood mononuclear cells and in the
endometrium decreased by 90–91% and 89–96%, respectively,
during treatment, and these inhibition levels remained high also
1 month after the treatments (Pohl et al., 2014). E2MATE and
NETA have been further studied in endometriosis patients in a
phase II study (EudraCT Number: 2011-005167-24), although at
present, no results are publicly available.
CONCLUSIONS AND PERSPECTIVES
The STS pathway is clearly implicated in local estrogen
formation, and is thus also associated with enhanced estrogen
actions. A vast amount of data supports an important role for STS
in hormone-dependent diseases, including gynecological diseases
like endometrial cancer, ovarian cancer, endometriosis, and
adenomyosis, and indirectly also in uterine fibroids. However,
the clinical studies that have evaluated STS inhibitors in
gynecological diseases to date have not provided convincing
data. Although the dual STS and aromatase inhibitors and
dual action inhibitors/antiestrogens might provide better clinical
performances compared to the classical STS inhibitors, these
agents have not reached clinical studies to date. As the intricate
local estrogen formation also depends on membrane transport
of the sulfated steroids, this aspect needs to be investigated
more in detail. This knowledge might contribute to a logical
interpretation of the clinical studies to date, and might lead to
the identification of novel drug targets and combined treatments
that will target individual transporters and the STS enzyme.
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